Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
hUC-MSC-sEV-002 nebulizer in allergic rhinitis with asthma
ChiCTR2600116255Phase 2Not yet recruiting
- Sponsor
- The Affiliated Hospital of Qingdao University
- Start
- Jan 2026
- Modality
- Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2 trial of hUC-MSC-sEV-002 in allergic rhinitis (AR) and asthma (2 arms), sponsored by The Affiliated Hospital of Qingdao University. Primary endpoints: Drug-related adverse reaction rate, Changes from baseline in vital signs and safety labs at 2 weeks and 2 more. Planned start Jan 2026; status: not yet recruiting.
02
Drugs
hUC-MSC-sEV-002
03
Conditions
allergic rhinitis (AR)asthma
Beyond the preview
Go deeper on ChiCTR2600116255.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600116255.